Rhumbline Advisers Decreases Holdings in Ralliant Corporation $RAL

Rhumbline Advisers lowered its stake in shares of Ralliant Corporation (NYSE:RAL) by 17.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 264,705 shares of the company’s stock after selling 56,277 shares during the period. Rhumbline Advisers owned about 0.23% of Ralliant worth $11,576,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Cullen Frost Bankers Inc. purchased a new position in Ralliant during the second quarter worth about $144,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Ralliant during the 2nd quarter worth approximately $1,410,000. JPMorgan Chase & Co. acquired a new stake in shares of Ralliant during the 2nd quarter worth approximately $18,494,000. Allspring Global Investments Holdings LLC raised its position in shares of Ralliant by 5,269.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 317,038 shares of the company’s stock valued at $14,000,000 after buying an additional 311,134 shares during the period. Finally, Boston Partners acquired a new position in Ralliant in the second quarter valued at approximately $63,656,000.

Ralliant Price Performance

Shares of RAL opened at $43.78 on Friday. The firm has a market capitalization of $4.94 billion and a price-to-earnings ratio of 22.34. The firm’s fifty day simple moving average is $50.19 and its 200-day simple moving average is $46.51. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $57.02. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The business had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. The business’s revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant’s dividend payout ratio is 10.20%.

Insiders Place Their Bets

In related news, Director Anelise Angelino Sacks purchased 2,000 shares of the company’s stock in a transaction on Monday, February 9th. The shares were bought at an average cost of $41.25 per share, for a total transaction of $82,500.00. Following the completion of the purchase, the director directly owned 5,403 shares of the company’s stock, valued at approximately $222,873.75. This trade represents a 58.77% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kate Mitchell acquired 2,350 shares of Ralliant stock in a transaction dated Tuesday, February 10th. The shares were bought at an average price of $42.48 per share, with a total value of $99,828.00. Following the transaction, the director directly owned 8,411 shares in the company, valued at approximately $357,299.28. The trade was a 38.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 8,145 shares of company stock valued at $332,233.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RAL shares. Barclays cut their target price on Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Vertical Research raised Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research report on Friday, February 6th. Truist Financial decreased their target price on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Weiss Ratings lowered shares of Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research note on Thursday, February 5th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $45.00 price target on shares of Ralliant in a research note on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $50.50.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.